Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The effect of probiotic administration on the severity of AD in adults has shown inconsistent results. To determine the effectiveness of probiotic supplementation as a therapeutic tool for adult AD. PubMed, Scopus a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental dermatology 2023-12, Vol.49 (1), p.46-52
Hauptverfasser: Husein-ElAhmed, Husein, Steinhoff, Martin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 52
container_issue 1
container_start_page 46
container_title Clinical and experimental dermatology
container_volume 49
creator Husein-ElAhmed, Husein
Steinhoff, Martin
description Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The effect of probiotic administration on the severity of AD in adults has shown inconsistent results. To determine the effectiveness of probiotic supplementation as a therapeutic tool for adult AD. PubMed, Scopus and Embase were systematically searched to collect data from studies in which probiotics were administered to treat adult AD. Out of 413 publications, 9 papers were included in the meta-analysis. Significant differences in the ScORing Atopic Dermatitis tool favouring probiotics were observed [relative risk (RR) -5.93, 95% confidence interval (CI) -8.43 to -3.43]. Lactobacillus salivarius presented with largest effect size (RR -9.79, 95% CI -13.04 to -6.54), followed by L. acidophilus (RR -5.77, 95% CI -10.82 to -0.72) and L. plantarum (RR -3.76, 95% CI -6.36 to -1.16). No benefit was observed with L. fermentum. Based on the severity of AD, probiotics showed better results in people with moderate-to-severe AD (RR -9.12, 95% CI -12.17 to -6.08) than in individuals with mild disease (RR -2.67, 95% CI -4.67 to -0.66). Serum levels of IgE and eosinophil count remained significantly unchanged after the probiotic intervention (RR 0.25, 95% CI -0.10 to 0.60; RR -0.27, 95% CI -0.68 to 0.13, respectively). Current evidence supports a role for some probiotics as a therapeutic tool for the treatment of adult AD, particularly in patients with severe AD. The efficacy of probiotics is strain specific, with L. salivarius and L. acidophilus having the largest clinical benefit. Such benefit is apparently independent of IgE levels and eosinophil count. Despite these encouraging results, the decrease in AD severity did not translate into a clinically meaningful better quality of life as assessed by the Dermatology Life Quality Index. There currently is not enough reliable data to reach conclusions about the optimal dose and duration for probiotic treatment.
doi_str_mv 10.1093/ced/llad318
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2864896996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2864896996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c219t-965207f5182a66a8b62a166dfa54053b7bc698d9b1d5a4c492edd78466e3ccfb3</originalsourceid><addsrcrecordid>eNo1kEtLAzEURoMotlZX7iVLQcbmMZNJ3EmpDyi40fWQSW4wMi8nGUv_vSltV5d7v8MH9yB0S8kjJYovDdhl02jLqTxDc8pFkTHGyTmaE07KTCguZ-gqhB9CKKdlcYlmvCyJyLmYo2btHJgYcO_wMPa176M3OEzD0EALXdTR9x32HdZ2aiLe-viNdeyHBFkY2xRHH56wxmEXIux3g0f487A9sC1EnelON7vgwzW6cLoJcHOcC_T1sv5cvWWbj9f31fMmM4yqmClRMFK6gkqmhdCyFkxTIazTRU4KXpe1EUpaVVNb6NzkioG1pcyFAG6Mq_kC3R9600e_E4RYtT4YSJI66KdQMSlyqYRSIqEPB9SMfQgjuGoYfavHXUVJtddbJb3VUW-i747FU92m-4k9-eT_OoF5Pw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864896996</pqid></control><display><type>article</type><title>Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Husein-ElAhmed, Husein ; Steinhoff, Martin</creator><creatorcontrib>Husein-ElAhmed, Husein ; Steinhoff, Martin</creatorcontrib><description>Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The effect of probiotic administration on the severity of AD in adults has shown inconsistent results. To determine the effectiveness of probiotic supplementation as a therapeutic tool for adult AD. PubMed, Scopus and Embase were systematically searched to collect data from studies in which probiotics were administered to treat adult AD. Out of 413 publications, 9 papers were included in the meta-analysis. Significant differences in the ScORing Atopic Dermatitis tool favouring probiotics were observed [relative risk (RR) -5.93, 95% confidence interval (CI) -8.43 to -3.43]. Lactobacillus salivarius presented with largest effect size (RR -9.79, 95% CI -13.04 to -6.54), followed by L. acidophilus (RR -5.77, 95% CI -10.82 to -0.72) and L. plantarum (RR -3.76, 95% CI -6.36 to -1.16). No benefit was observed with L. fermentum. Based on the severity of AD, probiotics showed better results in people with moderate-to-severe AD (RR -9.12, 95% CI -12.17 to -6.08) than in individuals with mild disease (RR -2.67, 95% CI -4.67 to -0.66). Serum levels of IgE and eosinophil count remained significantly unchanged after the probiotic intervention (RR 0.25, 95% CI -0.10 to 0.60; RR -0.27, 95% CI -0.68 to 0.13, respectively). Current evidence supports a role for some probiotics as a therapeutic tool for the treatment of adult AD, particularly in patients with severe AD. The efficacy of probiotics is strain specific, with L. salivarius and L. acidophilus having the largest clinical benefit. Such benefit is apparently independent of IgE levels and eosinophil count. Despite these encouraging results, the decrease in AD severity did not translate into a clinically meaningful better quality of life as assessed by the Dermatology Life Quality Index. There currently is not enough reliable data to reach conclusions about the optimal dose and duration for probiotic treatment.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1093/ced/llad318</identifier><identifier>PMID: 37706436</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Dermatitis, Atopic - drug therapy ; Humans ; Immunoglobulin E ; Probiotics - therapeutic use ; Quality of Life ; Skin</subject><ispartof>Clinical and experimental dermatology, 2023-12, Vol.49 (1), p.46-52</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c219t-965207f5182a66a8b62a166dfa54053b7bc698d9b1d5a4c492edd78466e3ccfb3</citedby><cites>FETCH-LOGICAL-c219t-965207f5182a66a8b62a166dfa54053b7bc698d9b1d5a4c492edd78466e3ccfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37706436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Husein-ElAhmed, Husein</creatorcontrib><creatorcontrib>Steinhoff, Martin</creatorcontrib><title>Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The effect of probiotic administration on the severity of AD in adults has shown inconsistent results. To determine the effectiveness of probiotic supplementation as a therapeutic tool for adult AD. PubMed, Scopus and Embase were systematically searched to collect data from studies in which probiotics were administered to treat adult AD. Out of 413 publications, 9 papers were included in the meta-analysis. Significant differences in the ScORing Atopic Dermatitis tool favouring probiotics were observed [relative risk (RR) -5.93, 95% confidence interval (CI) -8.43 to -3.43]. Lactobacillus salivarius presented with largest effect size (RR -9.79, 95% CI -13.04 to -6.54), followed by L. acidophilus (RR -5.77, 95% CI -10.82 to -0.72) and L. plantarum (RR -3.76, 95% CI -6.36 to -1.16). No benefit was observed with L. fermentum. Based on the severity of AD, probiotics showed better results in people with moderate-to-severe AD (RR -9.12, 95% CI -12.17 to -6.08) than in individuals with mild disease (RR -2.67, 95% CI -4.67 to -0.66). Serum levels of IgE and eosinophil count remained significantly unchanged after the probiotic intervention (RR 0.25, 95% CI -0.10 to 0.60; RR -0.27, 95% CI -0.68 to 0.13, respectively). Current evidence supports a role for some probiotics as a therapeutic tool for the treatment of adult AD, particularly in patients with severe AD. The efficacy of probiotics is strain specific, with L. salivarius and L. acidophilus having the largest clinical benefit. Such benefit is apparently independent of IgE levels and eosinophil count. Despite these encouraging results, the decrease in AD severity did not translate into a clinically meaningful better quality of life as assessed by the Dermatology Life Quality Index. There currently is not enough reliable data to reach conclusions about the optimal dose and duration for probiotic treatment.</description><subject>Adult</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Probiotics - therapeutic use</subject><subject>Quality of Life</subject><subject>Skin</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEURoMotlZX7iVLQcbmMZNJ3EmpDyi40fWQSW4wMi8nGUv_vSltV5d7v8MH9yB0S8kjJYovDdhl02jLqTxDc8pFkTHGyTmaE07KTCguZ-gqhB9CKKdlcYlmvCyJyLmYo2btHJgYcO_wMPa176M3OEzD0EALXdTR9x32HdZ2aiLe-viNdeyHBFkY2xRHH56wxmEXIux3g0f487A9sC1EnelON7vgwzW6cLoJcHOcC_T1sv5cvWWbj9f31fMmM4yqmClRMFK6gkqmhdCyFkxTIazTRU4KXpe1EUpaVVNb6NzkioG1pcyFAG6Mq_kC3R9600e_E4RYtT4YSJI66KdQMSlyqYRSIqEPB9SMfQgjuGoYfavHXUVJtddbJb3VUW-i747FU92m-4k9-eT_OoF5Pw</recordid><startdate>20231219</startdate><enddate>20231219</enddate><creator>Husein-ElAhmed, Husein</creator><creator>Steinhoff, Martin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231219</creationdate><title>Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis</title><author>Husein-ElAhmed, Husein ; Steinhoff, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c219t-965207f5182a66a8b62a166dfa54053b7bc698d9b1d5a4c492edd78466e3ccfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Probiotics - therapeutic use</topic><topic>Quality of Life</topic><topic>Skin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Husein-ElAhmed, Husein</creatorcontrib><creatorcontrib>Steinhoff, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Husein-ElAhmed, Husein</au><au>Steinhoff, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2023-12-19</date><risdate>2023</risdate><volume>49</volume><issue>1</issue><spage>46</spage><epage>52</epage><pages>46-52</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><abstract>Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The effect of probiotic administration on the severity of AD in adults has shown inconsistent results. To determine the effectiveness of probiotic supplementation as a therapeutic tool for adult AD. PubMed, Scopus and Embase were systematically searched to collect data from studies in which probiotics were administered to treat adult AD. Out of 413 publications, 9 papers were included in the meta-analysis. Significant differences in the ScORing Atopic Dermatitis tool favouring probiotics were observed [relative risk (RR) -5.93, 95% confidence interval (CI) -8.43 to -3.43]. Lactobacillus salivarius presented with largest effect size (RR -9.79, 95% CI -13.04 to -6.54), followed by L. acidophilus (RR -5.77, 95% CI -10.82 to -0.72) and L. plantarum (RR -3.76, 95% CI -6.36 to -1.16). No benefit was observed with L. fermentum. Based on the severity of AD, probiotics showed better results in people with moderate-to-severe AD (RR -9.12, 95% CI -12.17 to -6.08) than in individuals with mild disease (RR -2.67, 95% CI -4.67 to -0.66). Serum levels of IgE and eosinophil count remained significantly unchanged after the probiotic intervention (RR 0.25, 95% CI -0.10 to 0.60; RR -0.27, 95% CI -0.68 to 0.13, respectively). Current evidence supports a role for some probiotics as a therapeutic tool for the treatment of adult AD, particularly in patients with severe AD. The efficacy of probiotics is strain specific, with L. salivarius and L. acidophilus having the largest clinical benefit. Such benefit is apparently independent of IgE levels and eosinophil count. Despite these encouraging results, the decrease in AD severity did not translate into a clinically meaningful better quality of life as assessed by the Dermatology Life Quality Index. There currently is not enough reliable data to reach conclusions about the optimal dose and duration for probiotic treatment.</abstract><cop>England</cop><pmid>37706436</pmid><doi>10.1093/ced/llad318</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0307-6938
ispartof Clinical and experimental dermatology, 2023-12, Vol.49 (1), p.46-52
issn 0307-6938
1365-2230
language eng
recordid cdi_proquest_miscellaneous_2864896996
source Oxford University Press Journals All Titles (1996-Current); MEDLINE
subjects Adult
Dermatitis, Atopic - drug therapy
Humans
Immunoglobulin E
Probiotics - therapeutic use
Quality of Life
Skin
title Effects of probiotic supplementation in adult with atopic dermatitis: a systematic review with meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T10%3A51%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20probiotic%20supplementation%20in%20adult%20with%20atopic%20dermatitis:%20a%20systematic%20review%20with%20meta-analysis&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Husein-ElAhmed,%20Husein&rft.date=2023-12-19&rft.volume=49&rft.issue=1&rft.spage=46&rft.epage=52&rft.pages=46-52&rft.issn=0307-6938&rft.eissn=1365-2230&rft_id=info:doi/10.1093/ced/llad318&rft_dat=%3Cproquest_cross%3E2864896996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2864896996&rft_id=info:pmid/37706436&rfr_iscdi=true